Xuya Huang1, Fiona Catherine Moreton1, Dheeraj Kalladka1, Bharath Kumar Cheripelli1, Rachael MacIsaac1, R Campbell Tait1, Keith W Muir2. 1. From the Institute of Neuroscience and Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom (X.H., F.C.M., D.K., B.K.C., K.W.M.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (R.M.); and Haematology Department, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom (R.C.T.). 2. From the Institute of Neuroscience and Psychology, University of Glasgow, Queen Elizabeth University Hospital, Glasgow, United Kingdom (X.H., F.C.M., D.K., B.K.C., K.W.M.); Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom (R.M.); and Haematology Department, Glasgow Royal Infirmary, NHS Greater Glasgow and Clyde, Glasgow, United Kingdom (R.C.T.). keith.muir@glasgow.ac.uk.
Abstract
BACKGROUND AND PURPOSE: We compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. METHODS: Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment, 3 to 12 hours, and 24±3 hours post-intravenous thrombolysis for analyses of plasminogen, plasminogen activator inhibitor-1, d-dimer, factor V, fibrinogen, and fibrin(ogen) degradation products, in addition to routine coagulation assays. Related sample Wilcoxon signed-rank tests were used to test the within-group changes, and independent Mann-Whitney tests for between-group differences. RESULTS:Thirty patients were included (alteplase=14 and tenecteplase=16) with similar baseline demographics. Compared with baseline, alteplase caused significant hypofibrinogenaemia (P=0.002), prolonged prothrombin time (P=0.011), hypoplasminogenaemia (P=0.001), and lower factor V (P=0.002) at 3 to 12 hours after administration with persistent hypofibrinogenaemia at 24 hours (P=0.011), whereas only minor hypoplasminogenaemia (P=0.029) was seen in the tenecteplase group. Tenecteplase consumed less plasminogen (P<0.001) and fibrinogen (P=0.002) compared with alteplase. CONCLUSIONS: In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
RCT Entities:
BACKGROUND AND PURPOSE: We compared the fibrinolytic activity of tenecteplase and alteplase in patients with acute ischemic stroke, and explored the association between hypofibrinogenaemia and intracerebral hemorrhage. METHODS: Venous blood samples from a subgroup of participants in the Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST) study were obtained at pretreatment, 3 to 12 hours, and 24±3 hours post-intravenous thrombolysis for analyses of plasminogen, plasminogen activator inhibitor-1, d-dimer, factor V, fibrinogen, and fibrin(ogen) degradation products, in addition to routine coagulation assays. Related sample Wilcoxon signed-rank tests were used to test the within-group changes, and independent Mann-Whitney tests for between-group differences. RESULTS: Thirty patients were included (alteplase=14 and tenecteplase=16) with similar baseline demographics. Compared with baseline, alteplase caused significant hypofibrinogenaemia (P=0.002), prolonged prothrombin time (P=0.011), hypoplasminogenaemia (P=0.001), and lower factor V (P=0.002) at 3 to 12 hours after administration with persistent hypofibrinogenaemia at 24 hours (P=0.011), whereas only minor hypoplasminogenaemia (P=0.029) was seen in the tenecteplase group. Tenecteplase consumed less plasminogen (P<0.001) and fibrinogen (P=0.002) compared with alteplase. CONCLUSIONS: In patients with acute ischemic stroke, alteplase 0.9 mg/kg caused significant disruption of the fibrinolytic system, whereas tenecteplase 0.25 mg/kg did not, consistent with the trend toward lower intracerebral hemorrhage incidence with tenecteplase in the ATTEST study. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01472926.
Authors: Peter J McCartney; Hany Eteiba; Annette M Maznyczka; Margaret McEntegart; John P Greenwood; Douglas F Muir; Saqib Chowdhary; Anthony H Gershlick; Clare Appleby; James M Cotton; Andrew Wragg; Nick Curzen; Keith G Oldroyd; Mitchell Lindsay; J Paul Rocchiccioli; Aadil Shaukat; Richard Good; Stuart Watkins; Keith Robertson; Christopher Malkin; Lynn Martin; Lynsey Gillespie; Thomas J Ford; Mark C Petrie; Peter W Macfarlane; R Campbell Tait; Paul Welsh; Naveed Sattar; Robin A Weir; Keith A Fox; Ian Ford; Alex McConnachie; Colin Berry Journal: JAMA Date: 2019-01-01 Impact factor: 56.272
Authors: Jean-Philippe Desilles; Lucas Di Meglio; Francois Delvoye; Benjamin Maïer; Michel Piotin; Benoît Ho-Tin-Noé; Mikael Mazighi Journal: Front Neurol Date: 2022-07-06 Impact factor: 4.086
Authors: Bijoy K Menon; Fahad S Al-Ajlan; Mohamed Najm; Josep Puig; Mar Castellanos; Dar Dowlatshahi; Ana Calleja; Sung-Il Sohn; Seong H Ahn; Alex Poppe; Robert Mikulik; Negar Asdaghi; Thalia S Field; Albert Jin; Talip Asil; Jean-Martin Boulanger; Eric E Smith; Shelagh B Coutts; Phil A Barber; Simerpreet Bal; Suresh Subramanian; Sachin Mishra; Anurag Trivedi; Sadanand Dey; Muneer Eesa; Tolulope Sajobi; Mayank Goyal; Michael D Hill; Andrew M Demchuk Journal: JAMA Date: 2018-09-11 Impact factor: 56.272
Authors: Lars Kellert; Frank Arne Wollenweber; Götz Thomalla; Christian H Nolte; Jens Fiehler; Peter Arthur Ringleb; Franziska Dorn Journal: Eur Stroke J Date: 2017-08-17
Authors: Ze Zheng; Lalitha Nayak; Wei Wang; Arif Yurdagul; Xiaobo Wang; Bishuang Cai; Stephanie Lapping; Lale Ozcan; Rajasekhar Ramakrishnan; Richard G Pestell; Mukesh K Jain; Ira Tabas Journal: Blood Date: 2018-12-01 Impact factor: 25.476
Authors: Arezoo Khosravi; Hadi Baharifar; Mohamad Hasan Darvishi; Ali Akbar Karimi Zarchi Journal: IET Nanobiotechnol Date: 2020-12 Impact factor: 1.847
Authors: Peter J McCartney; Annette M Maznyczka; Hany Eteiba; Margaret McEntegart; Keith G Oldroyd; John P Greenwood; Neil Maredia; Matthias Schmitt; Gerry P McCann; Timothy Fairbairn; Elisa McAlindon; Campbell Tait; Paul Welsh; Naveed Sattar; Vanessa Orchard; David Corcoran; Thomas J Ford; Aleksandra Radjenovic; Ian Ford; Alex McConnachie; Colin Berry Journal: J Am Coll Cardiol Date: 2020-03-31 Impact factor: 24.094